174 related articles for article (PubMed ID: 37462445)
21.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
22. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
23.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
24. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutations and long-term survival in patients with thyroid cancer.
Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
[TBL] [Abstract][Full Text] [Related]
28. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.
Yeh TJ; Luo CW; Du JS; Huang CT; Wang MH; Chuang TM; Gau YC; Cho SF; Liu YC; Hsiao HH; Chen LT; Pan MR; Wang HC; Moi SH
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979671
[TBL] [Abstract][Full Text] [Related]
29. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
30.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
31. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
32. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
[TBL] [Abstract][Full Text] [Related]
33. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
Annunziata C; Pezzuto F; Greggi S; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML
Int J Cancer; 2018 Sep; 143(5):1153-1161. PubMed ID: 29603728
[TBL] [Abstract][Full Text] [Related]
34. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
35. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.
Liu C; Liu Z; Chen T; Zeng W; Guo Y; Huang T
Sci Rep; 2016 Nov; 6():36990. PubMed ID: 27833153
[TBL] [Abstract][Full Text] [Related]
36. Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma.
Yilmaz I; Erkul BE; Ozturk Sari S; Issin G; Tural E; Terzi Kaya Terzi N; Karatay H; Celik M; Ulusan M; Bilgic B
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Jul; 130(1):63-70. PubMed ID: 32404253
[TBL] [Abstract][Full Text] [Related]
37. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Jin A; Xu J; Wang Y
Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
[TBL] [Abstract][Full Text] [Related]
38. How do
Mukhtar N; Alhamoudi K; Alswailem M; Alhindi H; Murugan AK; Alghamdi B; Alzahrani AS
Front Endocrinol (Lausanne); 2023; 14():1270796. PubMed ID: 37859987
[TBL] [Abstract][Full Text] [Related]
39. TERT promoter hotspot mutations in breast cancer.
Shimoi T; Yoshida M; Kitamura Y; Yoshino T; Kawachi A; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Ichimura K; Fukuda T; Fujiwara Y; Tamura K
Breast Cancer; 2018 May; 25(3):292-296. PubMed ID: 29222734
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]